What is the current stock price of Neurocrine Biosciences, Inc. (NBIX)?

As of the latest market data, Neurocrine Biosciences, Inc. (NBIX) is trading at $128.89. The stock has seen a loss of -2.09% today.

Does Neurocrine Biosciences, Inc. (NBIX) pay a dividend?

Based on current data, Neurocrine Biosciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Neurocrine Biosciences, Inc.?

The current market capitalization of Neurocrine Biosciences, Inc. (NBIX) is approximately unavailable.

NBIX

Neurocrine Biosciences, Inc.·Healthcare

128.89

2.089%(−2.75)

Market Closed

135.15

4.857%(+6.26)

After Hours

Last Updated: — ET

52W L: $92.3152W H: $160.18

NBIX NEWS

defenseworld.net

1d ago

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Neurocrine Biosciences, Inc. (NASDAQ: NBIX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-two research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation, sixteen have given a buy recommendation and one has

reuters.com

3d ago

Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover

Soleno Therapeutics said on Tuesday it has voluntarily withdrawn the European marketing application for its rare metabolic disorder drug following acquirer Neurocrine's ‌plans to sharpen focus on the U.S. market.

gurufocus.com

4d ago

Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium

Neurocrine Biosciences (NBIX) is moving to acquire Soleno Therapeutics (SLNO) for $2.9 billion in a deal that could expand its presence in rare genetic disorder

seekingalpha.com

4d ago

Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript

proactiveinvestors.com

4d ago

Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal

Neurocrine Biosciences (NASDAQ:NBIX) has agreed to acquire Soleno Therapeutics (NASDAQ:SLNO) in an all-cash transaction valued at approximately $2.9 billion, it was announced on Monday. Under the terms of the agreement, Neurocrine will pay $53 per share for Soleno, representing a premium of about 34% over Soleno's closing stock price on April 2, 2026, and roughly 51% above its 30-day average.

wsj.com

4d ago

Neurocrine to Buy Soleno for $2.9 Billion

Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion in a move intended to expand its endocrinology and rare-disease portfolio.

Company Profile

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

1,800

IPO Date

1996-05-23

Beta

0.35

Websitewww.neurocrine.com↗